In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
OCRA Sponsors NCCN 2025 Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in October 2025 to reflect NCCN’s release of the 2025 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2025 Patient Guidelines for Cervical, Ovarian, and Uterine Cancer. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful guides for anyone newly diagnosed to help … Continued
OCRA’s Survivors Teaching Students Program Spotlighted by Fort Worth Star-Telegram
In a recent article for the Fort Worth Star-Telegram, Jeff Guttenfelder spoke with journalist Ciara McCarthy about losing his late wife, Ni, to ovarian cancer, and how he is channeling his grief into action through participation in OCRA’s Survivors Teaching Students program. Read the article “Fort Worth man’s wife died of ovarian cancer” in the … Continued
KVIA-TV ABC-7 Features OCRA-Funded Research Developing Nanotechnology for Ovarian Cancer Detection
KVIA-TV ABC-7 News El Paso recently spotlighted the groundbreaking work of OCRA-funded researcher Daniel Heller, PhD of Memorial Sloan Kettering Cancer Center, whose research lab is working to develop a liquid biopsy that uses nanotechnology and artificial intelligence (AI) to detect ovarian cancer earlier. We’re developing a liquid biopsy that uses nano sensors and AI … Continued